Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer

Cervical cancer is the number one cause of gynecological cancer death worldwide[1]. It is the fourth most frequent cancer in women globally, ranking after breast cancer (2 ·1 million cases), colorectal cancer (0·8 million) and lung cancer (0·7 million)[2]. It is estimated that 604,127 patients were diagnosed with the disease worldwide in 2020[1].Fig 1.

Source: Cancer Treatment Reviews - May 21, 2021 Category: Cancer & Oncology Authors: F.J. Crowley, R.E. O'Cearbhaill, D.C. Collins Tags: Anti-tumour Treatment Source Type: research